Literature DB >> 18308148

Surgical management of inflammatory breast cancer.

S Eva Singletary1.   

Abstract

Multimodality therapy consisting of primary chemotherapy, mastectomy, and radiotherapy appears to offer the most favorable outcomes for patients with inflammatory breast carcinoma (IBC). Patients who respond well to chemotherapy are the best candidates for surgery; if response to chemotherapy is poor, radiotherapy should be undertaken before attempting surgery. The operative field must be wide enough to encompass all secondary skin changes, and every attempt should be made to assure negative margins. Breast-conserving surgery and sentinel lymph node biopsy are not appropriate for patients with IBC. However, there are no medical contraindications to breast reconstruction after mastectomy, although most clinicians prefer to wait until after the completion of radiotherapy before attempting this additional surgery.

Entities:  

Mesh:

Year:  2008        PMID: 18308148     DOI: 10.1053/j.seminoncol.2007.11.008

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  3 in total

1.  Long-term follow-up of breast-conserving therapy in patients with inflammatory breast cancer treated with neoadjuvant chemotherapy.

Authors:  Valentina Bonev; Maristella Evangelista; Jeon-Hor Chen; Min-Ying Su; Karen Lane; Rita Mehta; John Butler; David Hsiang
Journal:  Am Surg       Date:  2014-10       Impact factor: 0.688

2.  How do I treat inflammatory breast cancer?

Authors:  Della Makower; Joseph A Sparano
Journal:  Curr Treat Options Oncol       Date:  2013-03

3.  Immediate Breast Reconstruction for Inflammatory Breast Cancer: Trends in Use and Clinical Outcomes 2004-2016.

Authors:  Daniel I Hoffman; Patricia Mae G Santos; Macy Goldbach; Luke J Keele; Neil K Taunk; Hannah S Bogen; Laura Burkbauer; Rachel C Jankowitz; Joshua Fosnot; Liza C Wu; Gary M Freedman; Julia C Tchou
Journal:  Ann Surg Oncol       Date:  2021-07-16       Impact factor: 5.344

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.